Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 79

Results For "Medica"

3619 News Found

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals
Clinical Trials | March 20, 2026

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes


Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients
News | March 20, 2026

Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients

India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease


IIT Roorkee unveils cutting-edge molecular medicine facility
R&D | March 19, 2026

IIT Roorkee unveils cutting-edge molecular medicine facility

The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics


Trial milestone sparks hope for first long-term gastroparesis treatment
Clinical Trials | March 19, 2026

Trial milestone sparks hope for first long-term gastroparesis treatment

The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis


Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
News | March 18, 2026

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025


Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients
Drug Approval | March 18, 2026

Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients

The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options


Zydus, Lupin join forces to expand access to semaglutide in India
News | March 18, 2026

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus


Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option
News | March 17, 2026

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect